Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Boehringer Ingelheim
Chubb
Argus Health
Healthtrust
Deloitte

Generated: May 26, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,620,814

« Back to Dashboard

Which drugs does patent 6,620,814 protect, and when does it expire?

Patent 6,620,814 protects RANEXA and is included in one NDA.

This patent has ninety-eight patent family members in twenty-nine countries.

Summary for Patent: 6,620,814
Title: Sustained release ranolazine formulations
Abstract:A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
Inventor(s): Wolff; Andrew A. (San Francisco, CA), Baker; Fiona (Dumfermline, GB), Langridge; John (Wrexham, GB)
Assignee: CV Therapeutics, Inc. (Palo Alto, CA)
Application Number:10/256,993
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,620,814
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 6,620,814
Patent Claim Types:
see list of patent claims
Use; Dosage form; Delivery; Formulation; Composition;

Drugs Protected by US Patent 6,620,814

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Gilead RANEXA ranolazine TABLET, EXTENDED RELEASE;ORAL 021526-001 Feb 12, 2007 AB RX Yes Yes ➤ Sign Up ➤ Sign Up TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE ➤ Sign Up
Gilead RANEXA ranolazine TABLET, EXTENDED RELEASE;ORAL 021526-002 Jan 27, 2006 AB RX Yes No ➤ Sign Up ➤ Sign Up TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 6,620,814

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 022085 ➤ Sign Up
Argentina 052921 ➤ Sign Up
Argentina 053440 ➤ Sign Up
Austria 217794 ➤ Sign Up
Austria 285774 ➤ Sign Up
Australia 2001240092 ➤ Sign Up
Australia 2008207703 ➤ Sign Up
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Healthtrust
Express Scripts
Johnson and Johnson
Merck
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.